SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurocrine Biosciences (NBIX)
An SI Board Since July 1996
Posts SubjectMarks Bans Symbol
1834 74 0 NBIX
Emcee:  Billy Dunn Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1234Neurocrine Biosciences "outperform" Monday, June 21, 2004 1:02:16 PM Icebrg-6/22/2004
1233Neurocrine Biosciences Announces the Appointment of Corinne H. Lyle to its BoardIcebrg-6/9/2004
1232Neurocrine Biosciences Announces Study Showing Indiplon Immediate Release Safe fkeokalani'nui-5/4/2004
1231BoA made it worse, but the larger effect is systemic. finance.yahoo.comkeokalani'nui-5/4/2004
1230And I was thinking of selling cc's at $68. Rats. In any event, a number ofquidditch-5/4/2004
1229Neurocrine Biosciences downgraded to "neutral" Tuesday, May 04, 2004 Icebrg-5/4/2004
1228Saw that this morning before work and I thought precisely the same thing. I alsBiotech Jim-5/3/2004
1227I believe that the expired portion of the agreement was for a purchase price of scaram(o)uche-5/3/2004
1226FT: <i>Pfizer will acquire more biotechnology companies to fill out its piRCMac-5/3/2004
1225Neurocrine: sweet dreams for the twilight years Neurocrine Biosciences has compIcebrg-4/8/2004
122413-bagger, 13-bagger, 13-bagger....... and, still, the usual asterisk..... &qscaram(o)uche-4/7/2004
1223Diosynth Biotechnology is selected by NeoPharm to Produce IL13-PE38QQR for an Imscaram(o)uche-4/7/2004
1222Neurocrine Reports Two Additional Phase III Trials Demonstrating Indiplon Is Safscaram(o)uche-4/7/2004
1221And a second PR: [EDIT:] Lyons' presentation to the Wells Fargo Securities quidditch-3/24/2004
1220New PR from NBIX: Neurocrine's 'SLEEP' Study Demonstrates Highly Posquidditch-3/24/2004
1219<i>Nature AOP, published online 17 March 2004; doi:10.1038/nature02440 AMBiomaven-3/18/2004
1218huh?Madharry-3/12/2004
1217That's nice. When it comes to evaluating market size, likelihood of uptake keokalani'nui-3/12/2004
1216Leerink Swann & Company Initiates Coverage of Neurocrine Biosciences, Inc. (Icebrg-3/12/2004
12153/4/04 lehman brothers no slides <I> sleep maintenance : </I> forsoftware salesperson-3/5/2004
1214>> Mr. Risk says he didn't know the patient had tested positive for opscaram(o)uche-3/3/2004
1213<i>modified release formulation</i> That's great news - to my mBiomaven-3/2/2004
1212Neurocrine Reports Indiplon Effective in Treating Elderly Patients With Difficulmopgcw-3/2/2004
1211Again, they are short (no data) on two important value: WASO and TST. Maybe thisMiljenko Zuanic-3/1/2004
1210NBIX trying to steal a bit of SEPR thunder this morning: >>SAN DIEGO, Martuck-3/1/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News